# Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation

> **NCT04339101** · PHASE2 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 59 (actual)

## Conditions studied

- Acute Leukemia
- Hematologic and Lymphocytic Disorder
- Myelodysplastic Syndrome
- Primary Myelofibrosis
- Secondary Myelofibrosis

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Itacitinib Adipate
- **DRUG:** Melphalan
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **DRUG:** Sirolimus
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT04339101
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-11
- **Primary completion:** 2023-05-22
- **Final completion:** 2025-10-09
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2026-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04339101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04339101, "Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04339101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*